Skip to main content
Journal cover image

Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel.

Publication ,  Journal Article
Exaire, JE; Tcheng, JE; Kereiakes, DJ; Kleiman, NS; Applegate, RJ; Moliterno, DJ; ELECT Investigators,
Published in: Catheter Cardiovasc Interv
March 2005

The objectives of this study were to explore the rate of vascular complications using closure devices (CDs) vs. manual compression (MC) among percutaneous coronary intervention (PCI) patients receiving enoxaparin, clopidogrel, aspirin, and GP IIb/IIIa inhibitors. The Evaluating Enoxaparin Clotting Times (ELECT) study enrolled patients receiving enoxaparin, clopidogrel, and GP IIb/IIIa inhibitors when necessary. Any approved CD or MC was allowed post-PCI, and clinical outcome data were prospectively collected. Four hundred forty-five patients had anti-Xa levels measured by a core laboratory and by a novel point-of-care device that reports ENOX times. All received enoxaparin, aspirin, and clopidogrel, and 75% received a concomitant GP IIb/IIIa inhibitor. Major and minor bleeding were defined according to TIMI criteria. "Any bleeding" included the occurrence of access site complications including hematoma, significant rebleeding, or bleeding delaying hospital discharge. TIMI major plus minor bleeding occurred in 1.5% of the patients who received CD vs. 1.8% of patients with MC (P = 0.83). Any bleeding occurred in 12.2% of CD vs. 5.7% MC (P = 0.02), and in 9.5% of patients receiving GP IIb/IIIa inhibitor vs. 2.8% (P = 0.01) among those who did not. For patients receiving both a GP IIb/IIIa inhibitor and CD, any bleeding was observed in 13.7% vs. 3.4% (P = 0.006) among patients who received neither. While minor and major TIMI bleeding remained very low in both groups, CD was associated with a twofold increase in risk of any-bleeding event when compared to MC, especially when using GP IIb/IIIa inhibitors.

Duke Scholars

Published In

Catheter Cardiovasc Interv

DOI

ISSN

1522-1946

Publication Date

March 2005

Volume

64

Issue

3

Start / End Page

369 / 372

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Ticlopidine
  • Punctures
  • Postoperative Hemorrhage
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Myocardial Ischemia
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Exaire, J. E., Tcheng, J. E., Kereiakes, D. J., Kleiman, N. S., Applegate, R. J., Moliterno, D. J., & ELECT Investigators, . (2005). Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Catheter Cardiovasc Interv, 64(3), 369–372. https://doi.org/10.1002/ccd.20257
Exaire, J Emilio, James E. Tcheng, Dean J. Kereiakes, Neal S. Kleiman, Robert J. Applegate, David J. Moliterno, and David J. ELECT Investigators. “Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel.Catheter Cardiovasc Interv 64, no. 3 (March 2005): 369–72. https://doi.org/10.1002/ccd.20257.
Exaire JE, Tcheng JE, Kereiakes DJ, Kleiman NS, Applegate RJ, Moliterno DJ, et al. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Catheter Cardiovasc Interv. 2005 Mar;64(3):369–72.
Exaire, J. Emilio, et al. “Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel.Catheter Cardiovasc Interv, vol. 64, no. 3, Mar. 2005, pp. 369–72. Pubmed, doi:10.1002/ccd.20257.
Exaire JE, Tcheng JE, Kereiakes DJ, Kleiman NS, Applegate RJ, Moliterno DJ, ELECT Investigators. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Catheter Cardiovasc Interv. 2005 Mar;64(3):369–372.
Journal cover image

Published In

Catheter Cardiovasc Interv

DOI

ISSN

1522-1946

Publication Date

March 2005

Volume

64

Issue

3

Start / End Page

369 / 372

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Ticlopidine
  • Punctures
  • Postoperative Hemorrhage
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Myocardial Ischemia
  • Middle Aged
  • Male
  • Humans